Rated avoid: 81.5x sales, 166x earnings and RSI 75.6 before Nov 2 earnings. There's no valuation case for keeping any of it, so take the gains.
Thesis (avoid, position, conviction 58)
Thesis carried over from the 2026-10-13 run.
Bull: Palantir's growth is exceptional and broadening: Q2 2026 revenue of $1.935B grew 93% YoY (F-PLTR-1), led by US commercial revenue up 149% YoY to $764M (F-PLTR-2) — evidence that the AIP-driven commercial land-grab is accelerating, not just a government story. Profitability is now very high quality: GAAP operating margin was 47% (F-PLTR-3), the balance sheet holds $9.2B in cash/short-term treasuries (F-PLTR-4), and Q2 EPS beat estimates by 15.7% ($0.41 vs $0.3544, F-PLTR-12). Management raised FY2026 revenue guidance to $8.150–8.158B (F-PLTR-5), and the stock's uptrend is intact and well above all major moving averages (F-PLTR-9) with strong relative strength vs SPY (+52.7% over 3 months). The next catalyst is Q3 2026 earnings on 2026-11-02 with consensus looking for ~$2.221B revenue and $0.424 EPS — a beat-and-raise pattern that has repeated for several quarters could extend momentum further.
Bear: PLTR trades at a P/S of 81.5x and P/E of 166x (F-PLTR-11) — pricing in years of flawless 90%+ growth even though the growth rate is already decelerating on a trailing basis (28.8% CY23→CY24, 56.2% CY24→CY25; F-PLTR-6, F-PLTR-7) and Q2 2026's 93% YoY figure is lapping an easy prior-year comp. Technically the stock is extended: RSI14 is 75.6 (F-PLTR-10), it sits just 0.18% off its 52-week high (F-PLTR-8), and it's stretched well above its 20/50/200-day moving averages (F-PLTR-9), with ret_3m of +56% and ret_1m of +20%. At this valuation, any guidance miss, deceleration in US commercial growth from the 149% pace (F-PLTR-2), or broader multiple compression in high-beta AI/software names would produce an outsized drawdown — the stock has essentially no valuation cushion. Analyst sentiment, while net positive, is not unanimous (12 Strong Buy/16 Buy vs 9 Hold/1 Sell/1 Strong Sell, F-PLTR-13), implying the market already largely prices the bull case.
Valuation: Fundamentals are genuinely excellent (93% revenue growth, 47% GAAP operating margin, raised guidance), but the stock's P/S of 81.5x and P/E of 166x (F-PLTR-11) are far outside normal bounds even for hyper-growth software, pricing in a multi-year continuation of near-100% growth that is already showing signs of deceleration on a multi-year base (growth rate fell from ~56% to a Q2 93% YoY print that is flattered by an easier prior-year comp). There is no margin of safety in the current price for anything less than a continued perfect execution streak, and the technical setup (RSI 75.6, at 52-week highs) suggests the market has already front-run the next few quarters of good news.
Catalysts
2026-11-02: Q3 2026 earnings report; consensus estimate is EPS of $0.424 and revenue of approximately $2.221 billion — a miss or deceleration in US commercial growth could trigger sharp multiple compression given current valuation
Facts
F-PLTR-1: Palantir reported Q2 2026 revenue of $1.935 billion for the quarter ended June 30, 2026, up 93% year over year. (as of 2026-08-03)[E5523]source
F-PLTR-2: U.S. commercial revenue was $764 million in Q2 2026, up 149% year over year. (as of 2026-08-03)[E5523]source
F-PLTR-3: GAAP operating income was $912 million, or 47% of revenue, in Q2 2026. (as of 2026-08-03)[E5523]source
F-PLTR-4: Cash, cash equivalents, and short-term U.S. Treasury securities totaled $9.2 billion at the end of Q2 2026. (as of 2026-08-03)[E5523]source
F-PLTR-5: Palantir raised its FY 2026 revenue guidance to $8.150–$8.158 billion in its August 3, 2026 results release. (as of 2026-08-03)[E5523]source
F-PLTR-6: Annual revenue increased from $2.225 billion in CY2023 to $2.866 billion in CY2024, a calculated increase of approximately 28.8%. (as of 2026-10-13)[E5518]
F-PLTR-7: Annual revenue increased from $2.866 billion in CY2024 to $4.475 billion in CY2025, a calculated increase of approximately 56.2%. (as of 2026-10-13)[E5518]
F-PLTR-8: The stock closed at $208.67 on October 13, 2026, 0.18% below its 52-week closing high of $209.05. (as of 2026-10-13)[E5094]
F-PLTR-9: At the October 13, 2026 close, PLTR was above its 20-, 50-, and 200-day moving averages of $190.59, $180.36, and $152.48, respectively. (as of 2026-10-13)[E5094]
F-PLTR-10: PLTR's 14-day RSI was 75.6 on October 13, 2026. (as of 2026-10-13)[E5094]
F-PLTR-11: The supplied fundamentals report a P/E ratio of 166.27 and a price-to-sales ratio of 81.48. (as of 2026-10-13)[E5095]
F-PLTR-12: For Q2 2026, diluted EPS was $0.41 versus the supplied analyst estimate of $0.3544, a reported positive surprise of 15.69%. (as of 2026-10-13)[E5115]
F-PLTR-13: For September 2026, the analyst recommendation count was 12 Strong Buy, 16 Buy, 9 Hold, 1 Sell, and 1 Strong Sell. (as of 2026-10-13)[E5115]
Critic
O3 (major): Trimming to 5% leaves a meaningful holding in a stock the underlying thesis rates avoid primarily on valuation. Accepted: Position sold to zero ahead of Nov 2 earnings, given valuation at 166x earnings and 81.5x sales.
What would change the view
A pullback to the 50-day moving average (~$180) or 20-day MA (~$191) on otherwise strong fundamentals would improve the entry valuation enough to revisit a long stance
Q3 2026 results showing US commercial revenue growth reaccelerating or holding near 149% YoY alongside continued margin expansion would strengthen the bull case despite valuation
Evidence of durable, large multi-year government or commercial contracts that materially de-risk the growth trajectory (not currently in the brief) would raise conviction on the long side
Data quality
Quality score 96/100.
Gap: The quote block and several news items are timestamped October 14, 2026, after the context's stated date of October 13, 2026; those future-dated items were not used as current facts.
Gap: The supplied quarterly fundamentals series omits a December 2025 quarter, so a continuous quarterly comparison across that period is unavailable.